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ABSTRACT 
This study investigated the analgesic effects of a THC pro-drug in a rodent model 
of recurrent migraine. Rats received 4 nitroglycerin-induced (NTG: 10mg/kg/2ml) 
migraine episodes every third day for 12 days; saline, cremaphor-vehicle, propranolol 
(10mg/kg/ml), or THC-VAL-HS (0.5, 1.0, and 2.0 mg/kg/ml) were given IP 30 minutes 
before NTG. Behavioral endpoints of photosensitivity, activity, orbital tightening, and 
tactile allodynia were assessed 110 m after NTG. Migraine severity increased over the 
course of the four episodes, pointing toward chronification and an important step in 
model validation. However, neither propranolol nor THC-VAL-HS significantly 
attenuated any of the migraine-related endpoints. These data are in contrast with clinical 
reports that marijuana mitigates migraine severity. These findings suggest that higher 
doses of THC-VAL-HS and/or other cannabinoid constituents in marijuana may be 
responsible for such anecdotal anti-migraine activity of cannabis.  
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1. INTRODUCTION 
 Migraine is one of the most widespread and debilitating disorders known to man. 
Recent estimates reveal that roughly 14% of the population should expect to contend with 
migraines at some point in their lifetime (Stovner et al. 2007). Migraine also has a drastic 
effect on the quality of life of those that suffer from it. A large-scale survey (Terwindt et 
al. 2000) sought to discern the differences in quality of life between migraineurs and non-
migraineurs. For this survey, they administered a 36-item questionnaire measuring health 
quality across eight domains. This survey found a significant decrease in the quality of 
life of those who are affected by migraines, which was found to be inversely proportional 
to the frequency of migraine episodes. 
 Additionally, migraine has a staggering effect on society as a whole. In an 
epidemiological study (Leonardi et al. 2005), researchers sought to quantify migraine’s 
effect on the population by assigning Years Lived with Disability (YLD), which takes 
into account the effect of disability that the disease has on population health. Utilizing the 
World Health Organization’s global burden of disease data, migraine contributed to 
roughly 2% of lifetime YLDs. In a separate study, the economic burden of migraine was 
quantified. This study (Ferrari, 1998) relied upon data regarding patterns of healthcare 
use, direct costs in the form of drugs and hospital visits, and the indirect costs associated 
with reduced productivity at work, absence from work, and opportunity cost associated 
with the migraineur and their caretakers. This study found the direct cost of migraine to 
be roughly $9.4 billion and the indirect cost to be between $1.4 billion and $17.2 billion.  
 Typical migraine, as classified by the International Classification of Headache 
Disorders (ICHD-9), is characterized as recurrent pulsatile headaches and facial pain, 
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often accompanied by nausea and photophobia. As migraine trends from episodic to 
chronic, a number of physical endpoints present themselves. 85% of episodic migraineurs 
present photophobia or sensitivity to light (Rothrock et al 1996) and 79% present some 
form of cutaneous allodynia (Burstein et al. 2000). These clinical endpoints provide 
feasible measures of migraine symptoms and, as such, are relied upon experimentally. 
 Current treatment for migraine is problematic. To combat migraine, two main 
types of pharmaceuticals are utilized: abortives and prophylactics. The standard abortive 
used is sumatriptan, which is administered orally. In a double blind, placebo-controlled 
study in humans (Tfelt-Hanson, 1998), an orally administered 100 mg dose of 
sumatriptan was only 58% efficacious. In a separate study, a notable prophylactic, 
propranolol, had 79% efficacy, though with a very small sample size (n=19) (Weber et al 
1972). There is room for improvement when it comes to pharmaceuticals and the 
screening of potential therapies.  
Use of analgesics to treat migraine related pain can lead to another form of 
neurological pain called medication overuse headache (MOH). Roughly 4% of analgesic 
users overuse medication and roughly 1% of analgesic users suffer from medication 
overuse headache (Diener et al 2004). In fact, a separate epidemiological study (Castillo 
et al. 1998) found that 0.75% of migraineurs have their episodic migraine transformed 
into chronic daily headache by medication overuse. This transformation into chronic 
daily headache results from changes in the endocannabinoid system (Cupini et al. 2008).  
In this instance it is clear that not only are our current methods of treatment largely 
ineffective, but they may in fact be causing unnecessary harm to those who depend on 
them. 
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Having considered the shortcomings of the current methods of treatment, one is 
left to wonder where these shortcomings might originate. Largely, it is the inability of 
these models to relate closely to the clinical picture of migraine. This lack of translational 
relevance is problematic, because a model is only as good as the endpoints that it 
measures, and if a model does not mirror and measure the physical endpoints seen in the 
clinical picture, it cannot be utilized very effectively (Garner, 2014).  
 As migraine research has progressed, the translational relevance of available 
models has improved. The first generation of models sought to determine the effects of 
administered nitroglycerine (NTG) in rats on the outcome of some potentially relevant 
clinical endpoints (Tassorelli et al. 2003). For this experiment, rats were administered 
NTG and tested for signs of hyperalgesia, largely through the tail flick apparatus. This 
experiment found significant increases in hyperalgesia at 2 and 4 hours post-NTG 
injection. These results used clinically relevant induction and revealed the possible role 
of nitrovasodilators in pain modulation. Though this experimental format may have had 
its merits, it lacked translational relevance to the clinical picture. The clinical need 
focuses on episodic migraine, which is characterized by recurrent migraine episodes. 
Additionally, the endpoints measured in this current model of migraine are not diagnostic 
criteria for migraine in the clinical picture.  
In the second generation of migraine modelling, translational relevance improved 
by relying on multiple NTG administrations and migraine inductions (Pradhan et al. 
2013). In this experiment, mice were injected with NTG every other day for 9 days, 
resulting in 5 total NTG injections. This experiment found significant increases in 
hyperalgesia related to von Frey mechanical sensitivity (technically their endpoint 
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measured allodynia), and that these effects not only persisted, but worsened with episodic 
migraine induction. The implementation of recurrent NTG administration helped to 
improve the translational relevance of this migraine model, in regards to frequency, 
though they still neglected more clinically relevant endpoints of episodic migraine by 
focusing solely on hyperalgesia. 
The third generation of migraine models sought to include diagnostic endpoints in 
its assessment of episodic migraine (Sufka et al. 2016). This experiment subjected rats to 
5 NTG injections over the course of 15 days and measured the effect on the novel 
endpoints of expressed facial pain (using the Rat Grimace scale) and photophobia and 
decreased movement (both quantified using a Light/Dark box). The results of this 
experiment showed a significant decrease in locomotor activity and an increase in light 
sensitivity over the course of the five test sessions. The changes that this experiment 
introduced to the model allowed it to become more translationally relevant and come 
closer to modelling the clinical picture. 
 The final generation of modelling, and the one that is utilized in this experiment, 
sought to add another clinically relevant endpoint related to tactile allodynia (Harris et al. 
2017). This experiment followed the recurrent administration of NTG that previous 
models utilized, and added a new apparatus in an attempt to quantify the development of 
tactile allodynia associated with chronification of migraine. This new apparatus is a 
circular arena consisting of two half fields of sandpaper of differing grit and seeks to 
quantify movement data as well as preference for one half field or the other. Through the 
implementation of this new apparatus, a significant increase in tactile allodynia, as 
measured by a decrease in movement and a preference for spending time on the smoother 
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sandpaper, was recorded during the course of this experiment. However, this increase 
only occurred during the 5th episode, which points toward tactile allodynia related to the 
chronification of migraine. 
 Throughout history, a number of natural products have been utilized in the 
treatment of modern diseases. Oftentimes, through long-term trial and error related to 
ayurvedic medicine, a botanical treatment was found to be successful for reasons that 
would later become apparent when laboratory science could elaborate on its mechanism 
of action. In the case of headache, this has been demonstrated with the oral botanical 
therapies of Feverfew and Butterbur (Levin, 2012), which have been shown to be 
generally effective in the reduction of migraine frequency and in migraine prevention, 
respectively (Diener et al. 2005; Lipton et al. 2004). Feverfew was discovered to have a 
role as an inhibitor of prostaglandin synthesis (Pareek et al. 2011), which has been 
previously implicated in the onset of migraine (Antonova et al. 2012). 
 Additionally, anecdotal evidence points to the possible efficacy of cannabis in 
alleviating symptoms of migraine. As early as the year 700 B.C.E., Indian ayurvedic 
medicine touted the ability of cannabis to be utilized for migraine pain (Russo, 1998). 
These anecdotal reports continued and persist even to this day, attesting to the possible 
benefits of cannabis use for migraine treatment (Russo, 1998).  
 However, reports of the analgesic properties of cannabis extend beyond anecdotal 
evidence and transition to experimental data. A 1972 study sought to compare the 
analgesic properties of THC to those of morphine (Buxbaum, 1972). To accomplish this 
goal, rats were administered intraperitoneal injections of THC or morphine and then 
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subjected to hot plate and tail flick tests. This experiment found that an intraperitoneal 
injection of THC had analgesic effects equipotent to morphine in rats.  
 Furthermore, the analgesic effects of THC have also been demonstrated in human 
trials (Noyes Jr et al. 1975). Patients suffering from continuous pain attributed to cancer 
were administered varying doses of THC, and had their pain relief compared to the 
effects of codeine. This experiment found that a 20 mg dose of THC was slightly more 
effective at relief and reduction of pain than a 120 mg dose of codeine. This experiment 
speaks to the analgesic properties of THC and provides some validity for anecdotal 
efficacy in humans.  
 Finally, synthetic compounds that modulate the endocannabinoid system have 
been shown to have a positive effect on pain states related to NTG-induced migraine 
(Nozaki et al. 2015). Mice presenting varying gene knockouts were administered 
intraperitoneal nitroglycerin and then tested for mechanical sensitivity using von Frey 
testing methods. This experiment found a significant increase in the threshold of 
mechanical sensitivity in mice who had a knockout of the gene for fatty acid amide 
hydrolase (which metabolizes anandamide, a portion of the endocannabinoid system that 
interacts with CB1 and CB2 receptors). This modulation of the endocannabinoid system 
and its positive effects on pain management again point to the possibility of utilizing 
THC as an analgesic in migraine related pain.  
 The present study aims to build upon previous research and investigate the effects 
of a THC pro-drug formulation on a recurrent migraine model in rats. By utilizing 
clinically relevant induction, frequency of administration, and endpoints, this study aims 
to screen a novel pharmacotherapy for possible migraine treatment.  
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2. METHODS 
 
2.1. Subjects 
 Male Sprague Dawley Rats (225-280 g; Envigo, Indianapolis, IN) were housed in 
pairs in acrylic tubs with bedding material and maintained under a 12:12 hr light-dark 
cycle in a temperature and humidity controlled vivarium. Food and water were available 
ad libitum. Animals were handled twice daily for seven days preceding experimental 
manipulations to reduce experimenter-related stress. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee of the University of 
Mississippi (Protocol #15-021). 
2.2. Drug Administration 
 2.2.1 Migraine Induction 
 The NTG stock solution contained 5 mg/mL NTG dissolved in 30% alcohol, 30% 
propylene glycol, and water (American Regent; Shirley NY). NTG was administered in a 
volume of 2 mL/kg to achieve a dose of 10 mg/kg. Induction of episodic migraine 
episodes consisted of 4 NTG injections administered every third day over 12 days. Rats 
acclimated in the testing room for at least 1 hr in their home cages prior to behavioral 
testing. All behavioral tests were begun at 110 min post NTG injections. 
 2.2.2 Test Articles 
 The test article was a THC pro-drug, THC-mono-val mono-hemisuccinate (THC-
VAL-HS), administered at doses of 0.5, 1.0, and 2.0 mg/kg/mL (purity >98%). For a 
positive control, propranolol was used and was dissolved in saline. For our vehicle group, 
5 animals were assigned saline while 5 animals were assigned the THC-VAL-HS vehicle 
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of cremaphor (cremaphor/EtOH in water). All test articles were administered 60 min 
before NTG injection.  
2.3. Rat Grimace Scale 
 Orbital tightening, a facet of the Rat Grimace Scale, was utilized to quantify pain 
by examining facial features of a rat during a pain state. Images of the rat’s facial features 
were taken 90 min post NTG administration with a 5 megapixel, 1080p camera 
positioned 6 to 12 inches from the subject’s home cage. During this imaging, rats 
remained in their home cages to reduce experimental stress. Following the experiment, 
unlabeled images were displayed on a computer monitor for scoring by two trained 
research assistants who were blinded to condition. Images were scored for orbital 
tightening, nose/cheek flattening, and ear and whisker changes using a scale of 0-2 (not 
present, moderate, obvious). Scores were averaged across the two raters to produce an 
overall pain score for each rat. The inter-rater reliability between the two raters was 
0.840.  
2.4. Light/Dark Box 
 Light/Dark (L/D) box testing for photophobia and movement was conducted in a 
two chamber condition place preference apparatus (Med-Associates, St. Albans, VT) 
with chamber dimensions of 25.5 cm x 21.0 cm x 20.9 cm. Black construction paper was 
taped over the acrylic lid of the black chamber to reduce illumination. Under these 
conditions, lumens measured 260-266 in the white chamber and 0 lumens in the black 
chamber. Each chamber was equipped with infrared photobeam detectors to track animal 
activity. 110 min post NTG treatment administration, rats were placed in the corner of the 
white chamber facing away from the experimenter. The rats were then allowed to explore 
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the white and dark chambers for 20 min. Time spent in the white chamber during this 
period was measured and expressed in seconds. Total number of photo beam breaks in 
both chambers quantified activity.  
2.5. Arena Testing for Tactile Allodynia 
  Tactile allodynia was assessed using an open field arena (50.8 cm diameter with 
a 25.4 cm diameter sidewall). The arena floor was divided into two halves containing 
either 40 or 220 grit sandpaper. The 40 grit sandpaper contained low density (i.e., areas 
void of media) grains of large diameter (425 µm) rounded media, while the 220 grit 
sandpaper contained high density grains of small diameter (68 µm) jagged media. Animal 
activity was recorded by a camera mounted above the open field arena and analyzed on a 
computer equipped with Ethovisions XT software (Noldus, Holland) to track movement 
and time spent in each half of the arena. Ethovisions software also provided heat signal 
maps that tracked animal movement for the duration of the test. These tests were 
conducted immediately after L/D box testing. Rats were placed in the center of the arena 
facing away from the experimenter such that left and right paws made contact with the 
two grit surfaces. Animals were tracked for a 5 min period. 
2.6. Statistical analyses 
 Data were analyzed with SPSS software using one-way (between groups) 
ANOVAs or two-way (between and within groups) ANOVAs with post-hoc tests for 
simple effects (Fisher’s exact); one tailed testing with significance at p < .05. Because 
propranolol had a different vehicle from the THC-VAL-HS compound, the vehicle group 
for this experiment consisted of 5 animals receiving saline and 5 animals receiving the 
THC-VAL-HS vehicle (Cremaphor/EtOH in water).  
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3. RESULTS 
 
Weight Data 
A summary of weight gain across the recurring migraine protocol across 
treatment groups is summarized in Figure 1. Over the course of the study, rats in every 
treatment group consistently gained weight. In the day following a migraine episode, the 
average weight of every treatment group decreased before recovering its upward trend. 
Consistent with these descriptions, a two-way ANOVA revealed a significant main effect 
for Day [F(10,40) = 83.645, p < 0.001]. Additionally, there was no significant Treatment 
effect [F (5,40) = 1.805, p = 0.134] nor a significant Day x Treatment interaction 
[F(50,40) = 0.963, p = 0.549]. No further analyses were performed on these data.   
Orbital Tightening 
 The effects of repeated migraine episodes on orbital tightening across treatment 
groups are summarized in Figure 2. No systematic pattern showing changes or worsening 
of orbital tightening nor any separation among treatment groups in a consistent manner 
was detected from these data. For example, the two vehicle groups differed in their 
progression, whereby saline animals had consistent orbital tightening scores across the 4 
migraine episodes, whereas the cremaphor animals seemed to show a decrease in orbital 
tightening scores. Neither propranolol or THC-VAL-HS reliably reversed any patterns. 
Consistent with these observations, a two-way ANOVA failed to reveal a significant 
effect for Day [F(3,37) = 0.963, p = 0.421] or Treatment [F(5,37), p = 0.077], nor a 
significant Day x Treatment interaction [F(15,37) = 1.104, p = 0.363]. No further 
analyses were performed on these data.  
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L/D Box 
 The effects of repeated migraine episodes on mean movement in the Light/Dark 
box across treatment groups are summarized in Figure 3. All treatment groups showed a 
decrease in movement over the course of the four test sessions, with no group showing 
any kind of marked difference in this endpoint from any other group. Consistent with 
these observations, a two-way ANOVA revealed a main effect for Day [F(3,25) = 
10.547, p < 0.001] and failed to reveal an effect for Treatment [F(5,25) = 1.210, p = 
0.333]. Additionally, there was no significant Day x Treatment interaction [F(15,25) = 
1.553, p = 0.113]. A separate one-way ANOVA performed on the test sessions revealed 
no significant effect for Treatment in any session.  
 The effects of repeated migraine episodes on mean time in light in the Light/Dark 
box across treatment groups are summarized in Figure 4. Again, all treatment groups 
generally decreased over the course of the 4 NTG episodes. On the second migraine 
episode, the 0.5 THC-VAL-HS group displayed a sharp increase in time spent in light, 
followed by a decrease over the next two episodes. No group seems to be markedly 
higher than another group in this endpoint over the course of the 4 NTG episodes. 
Consistent with these observations, a two-way ANOVA revealed a main effect for Day 
[F(3,25) = 23.405, p < 0.001] while no significant effect was revealed for Treatment 
[F(5,25) = 1.537, p = 0.215], nor any significant Day x Treatment interaction [F(15,25) = 
0.918, p = 0.549]. A separate one-way ANOVA performed on test sessions 1-4 found 
significant effects for Treatment on test sessions 1, 2, and 4. On test session 1, the mean 
time in light score of the THC-VAL-HS 1.0 group was significantly higher than the mean 
time in light score of the propranolol group (p = 0.040). On test session 2, the mean time 
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in light score of the THC-VAL-HS 0.5 group was significantly higher than mean time in 
light score of the saline (p = 0.031), propranolol (p = 0.009), and THC-VAL-HS 1.0 
groups (p = 0.045). On test session 4, the mean time in light score of the THC-VAL-HS 
2.0 group was significantly higher than the mean time in light score of the propranolol 
group (p = 0.032).  
Open Arena 
 The effects of repeated migraine episodes on movement in the open arena across 
treatment groups are summarized in Figure 5. Over the course of the 4 NTG episodes, all 
groups decreased movement drastically from episode 1 to 2 and then slowly increased 
movement over the remaining episodes. No treatment group seemed to be markedly 
different in this endpoint from any other. A two-way ANOVA revealed a main effect for 
Day [F(3,40) = 279.893, p < 0.001] and a significant Day x Treatment interaction 
[F(15,40) = 2.033, p = 0.019] but failed to reveal a main effect for Treatment [F(5,40) = 
0.177, p = 0.970]. A one-way ANOVA performed on test sessions 1-4 showed a 
significant Treatment difference during episodes 2 and 4. In episode 2, the mean arena 
activity score of the THC-VAL-HS 0.5 and THC-VAL-HS 1.0 groups were significantly 
higher than the mean arena activity score of the saline group (p = 0.041 and p = 0.030). In 
test session 4, the mean arena activity score of the THC-VAL-HS 1.0 group was 
significantly lower than the mean arena activity score of the THC-VAL-HS 0.5 and THC-
VAL-HS 2.0 groups (p = 0.045 and p = 0.002).  
 The effects of repeated migraine episodes on time spent in half field (in this case, 
the 40 grit sandpaper half field) across treatment groups are summarized in Figure 6. All 
treatment groups followed the same pattern over the 4 test sessions. The first 3 sessions 
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remained relatively constant, followed by a sharp decrease from test session 3 to 4. There 
were no noticeable differences between each treatment group for this endpoint. 
Consistent with these observations, a two-way ANOVA found a significant main effect 
for Day [F(3,40) = 17.795, p < 0.001]. However, this analysis failed to reveal a main 
effect for Treatment [F(5,40) = 0.735, p = 0.602] nor any significant Day x Treatment 
interaction [F(15,40) = 1.228, p = 0.263]. A separate one-way ANOVA revealed a 
significant Treatment effect on test sessions 1 and 2. On test session 1, the mean 40 grit 
duration of the propranolol group was significantly higher than the mean 40 grit duration 
of the saline (p = 0.015) and THC-VAL-HS 2.0 groups (p = 0.031). On test session 2, the 
mean 40 grit duration of the propranolol group was significantly higher than the mean 40 
grit duration of the saline (p = 0.014) and THC-VAL-HS 2.0 groups (p = 0.025) while the 
mean 40 grit duration of the THC-VAL-HS 1.0 group was significantly higher than mean 
40 grit duration of the saline group (p = 0.040).  
4. DISCUSSION 
 
The goal of this research was to determine whether a recurrent NTG migraine 
protocol models the progression of migraine from episodic to chronic and to examine the 
effects of a THC pro-drug formulation in reducing migraine endpoints in this protocol. 
Rats received 4 recurring injections of NTG, with endpoints of facial pain, photophobia, 
activity, and tactile allodynia quantified after each exposure. We predicted that 1) 
evidence of chronification on these endpoints would be demonstrated by the recurrent 
NTG model, and 2) THC-VAL-HS, alongside the positive control of propranolol, would 
attenuate the relevant migraine endpoints.  
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 Human migraineurs often report an increased sensitivity to light and that activity 
exacerbates migraine intensity. In this current study, rats demonstrated a worsening of 
many clinically relevant endpoints. Across the 4 NTG administrations, rats showed 
increasing levels of photophobia, decreasing levels of motor activity in the light-dark 
apparatus and decreasing motor activity in the open arena. These findings are also 
consistent with previous studies that show the clinically-relevant migraine related 
endpoints of photophobia and reduced activity worsen after multiple NTG 
administrations (Pradhan et al. 2013; Sufka et al. 2016). Moreoever, these results are 
similar to symptoms present in human migraineurs and aligns with the ICHD-9 
diagnostic criteria.  
 Emergence of spontaneous allodynia is common among migraineurs with 
frequent episodes. Spontaneous allodynia is that which occurs to non-noxious stimuli 
from daily activities, and it is a diagnostic criterion for migraine chronification. In our 
recurrent NTG model, we found evidence of spontaneous allodynia in our open arena as 
episode frequency increased. In other NTG migraine models including single episode 
protocols, the most common migraine endpoint is an evoked allodynic response via von 
Frey procedure. However, evoked allodynia is not a clinically relevant endpoint and such 
measures suffer from poor translational relevance. It may be that spontaneous allodynia, 
as derived from the arena apparatus, offers a more translationally-relevant endpoint for 
migraine chronification and yield increased model validity. 
A common feature of migraine in humans is the presence of nausea and vomiting. 
There is no direct measure capable of quantifying nausea in rats, nor does this species 
vomit. However, we measured weight gain as an index of nausea and a loss of appetite. 
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Changes in weight gain may serve as a surrogate measure of nausea, which presumably 
decreases appetite. We hypothesized that, if migraine were to induce nausea and a loss of 
appetite, it would manifest in decreased food consumption and result in decreased weight 
gain following an episode.  Our measure of rodent weight over the entire protocol follows 
such a pattern and may mirror the clinical presentation of migraine. In the day following 
a migraine episode, the average weight of every treatment group decreased before 
recovering its upward trend. This “stairstep” trend signifies a decrease in appetite on days 
in which NTG was administered, and may reflect nausea often present during a migraine 
episode.  
The clinically-relevant behavioral measures in this recurrent NTG protocol align 
well with the ICHD-9 diagnostic criteria of migraine and migraine chronification. Animal 
models that demonstrate the greatest number of homologies to a clinical syndrome are 
considered the most valid (Garner 2014), and thus the similarity in findings between this 
study and previous research, which demonstrated chronification of migraine related 
endpoints over repeated NTG administration and the emergence of spontaneous tactile 
allodynia, (Harris et al. 2017) serves to add construct validity to this recurrent migraine 
model. 
 Propranolol is common prophylactic in migraine, with 78% efficacy (Weber 
1972). Though propranolol was predicted to act as an effective positive control and 
prophylactic agent, this group showed no reversal on any of the migraine-related 
endpoints on any episode. The failure to demonstrate propranolol’s efficacy in the model 
may be due to differences in drug administration in the current model with what is 
currently done in humans. In humans, propranolol is typically administered daily, 
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whereas in the current study it was administered intermittently and only 30 minutes 
before NTG administration. Pre-loading and daily administration in the current model 
may yield positive effects. Support for this idea comes from research which showed that 
the greatest decrease in hypertension in rats occurred when they were subjected to 
administration of propranolol that was both chronic and delivered before experimentation 
began (Lin 1991). In this experiment, the rats that were pre-administered propranolol 
began administration three days before the protocol commenced. Our current migraine 
protocol may benefit from a similar “pre-loading” of propranolol and may see it act as a 
positive control.  
 THC has been shown to have analgesic actions against a wide variety of 
nociceptive stimuli in rodents (Buxbaum 1972).  Anecdotal reports from humans suggest 
that cannabis use attenuates migraine (Russo 1998). In contrast to our predictions, THC-
VAL-HS failed to alter migraine related endpoints in this recurrent migraine model. 
There are three possible explanations for THC-VAL-HS’s ineffectiveness against 
migraine. First, it may be the case that THC is ineffective at modulating migraine 
endpoints in this type of model. A second possible explanation for lack of efficacy may 
be related to the use of a pro-drug with a different pharmaco-dynamic profile than pure 
THC.  The absence of an effect in our model may be related to the slower onset and low 
overall blood levels than the same dose of the pure compound because of its rate-limited 
conversion from pro-drug to pure THC. Thus, it may be necessary to utilize higher doses 
to achieve clinical benefit. A third possible explanation for the lack of effects may relate 
to the use of THC alone in the test compound. Cannabis may be effective at modulating 
migraine, but to do so would require many cannabinoids or non-cannabinoids 
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constituents in the plant extract. A study of marijuana extracts and fractions in this model 
would address this problem. 
 This experiment suffers from some limitations and has some opportunities to 
improve. First, orbital tightening is presented as an early indicator of photosensitivity, yet 
this measure is not temporally connected to measures of photosensitivity in the light-dark 
box. This experiment would benefit from having these two endpoints more closely 
linked, perhaps by removing subjects from the light-dark box to assess orbital tightening 
scores.  
Second, data about weight progression and its relation to migraine-induced nausea 
over the course of the recurrent migraine protocol is tenuous. Thus we can only infer that 
these changes in weight data are related to migraine induced nausea simply because it 
appears to mirror the clinical presentation of migraine. Evidence that body weight 
changes in this “staircase” design may be a surrogate measure for nausea could be 
obtained from an experiment that utilized a compound that was known to give animals 
nausea. Two possibilities to cross-validate this as a surrogate measure of nausea would be 
a) to find a similar protocol in which a feature of some administration has as a side effect 
of nausea or b) to utilize compounds that are commonly used to produce conditioned 
aversions. For the first approach, chemotherapy reveals itself as a possible solution. In 
this case, cisplatin is known to induce nausea in animals in a standard chemotherapy 
protocol should demonstrate this same “staircase” outcome in weight gain (Hesketh 
2008). This standard protocol could even be modified to administer cisplatin every third 
day so as to more closely relate to our recurrent NTG migraine protocol. For the second 
approach, injections of lithium chloride may be effective, as it is often utilized for 
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conditioned taste aversion (Nachman 1963). Utilizing one of these approaches would 
function as an effective cross-reference for our use of weight data as a surrogate measure 
of nausea.  
Third, the novel measure of spontaneous tactile allodynia in the open arena could 
benefit from having its findings validated with additional data. It would be beneficial to 
determine if this arena apparatus generalizes to other models that present spontaneous 
allodynia, such as a cisplatin-induced neuropathy model (Authier et al. 2000). If 
spontaneous allodynia in other models can be captured by the arena apparatus, the next 
step would be to determine whether spontaneous allodynia differs from evoked allodynia 
in pharmacological sensitivity. A previous experiment of this type (Cucinello et al. 2017) 
found gabapentin and oxycontin to be effective analgesics in the evoked allodynia 
measure of electronic von Frey, but only found oxycontin to be effective in the 
spontaneous allodynia measure. These results align with the clinical presentation in that 
oxycodone but not gabapentin is effective in managing allodynia.  
Finally, the absence of a prophylactic agent in attenuating these migraine 
endpoints is a limitation when it comes to drug screening. Model validity could be greatly 
improved with an increase in pharmacological sensitivity. Efficacious and non-
efficacious migraine therapies should screen positive and negative in the model, 
respectively, while also avoiding false positives and false negatives. 
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Figure	1.	Mean	body	weight	across	treatment	groups	during	migraine	induction	
protocol.	Each	data	point	represents	mean	group	body	weight	±	SEM.	
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Figure	2.	Mean	orbital	tightening	score	across	treatment	groups	over	four	NTG	test	
sessions.	Each	data	point	represents	group	mean	orbital	tightening	score	±	SEM.	Orbital	
tightening	was	assessed	30	min	post	NTG	administration	(20mg/kg).	
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Figure	3.	Mean	movement	in	Light/Dark	box	across	treatment	groups	over	four	NTG	test	
sessions.	Each	data	point	represents	group	mean	movement	(quantified	as	number	of	
photobeam	breaks)	±	SEM.	Movement	data	was	collected	110	min	post	IP	NTG	
administration	(20	mg/kg)	and	was	collected	over	a	20	minute	time	period.		
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Figure	4.	Mean	time	spent	in	light	portion	of	Light/Dark	box	across	treatment	groups	
over	four	NTG	test	sessions.	Each	data	point	represents	group	mean	time	spent	in	light	
±	SEM.	Light	data	was	collected	110	min	post	IP	NTG	administration	(20	mg/kg)	and	was	
collected	over	a	20	minute	time	period.	
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Figure	5.	Mean	activity	in	the	open	arena	across	treatment	groups	over	four	NTG	test	
sessions.	Each	data	point	represents	group	mean	arena	activity	(quantified	in	cm	
traveled)	±	SEM.	Arena	activity	data	was	collected	130	min	post	IP	NTG	administration	
(20mg/kg)	and	was	collected	over	a	5	minute	time	period.		
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Figure	6.	Mean	time	spent	on	40	grit	half	field	across	treatment	groups	over	four	NTG	
test	sessions.	Each	data	point	represents	group	mean	time	spent	on	the	40	grit	half	field	
±	SEM.	Data	was	collected	130	min	post	IP	NTG	administration	(20mg/kg)	and	was	
collected	over	a	5	minute	time	period.	
